
KRYS+73.39%14.3%

NTLA-50.51%14.3%

QURE-64.59%14.3%

RARE-51.71%14.3%

SLNO0.00%14.3%

SRPT-21.27%14.3%

SRRK+2.95%14.3%
As of Oct 9, 2026, 4:27 AM ET
Rare Diseases '25: Gene Therapy & Genetic Med Constituents
Intellia Therapeutics, Inc.NTLA | 14.3% | 7.60% | 10.33% | 3.19% | 3.96% | 40.16% | -8.56% | 72.60% | -50.51% | -29.57% | -89.56% | $1.76B |
Krystal Biotech, Inc.KRYS | 14.3% | 0.84% | -2.90% | -5.97% | 0.61% | 32.76% | 18.74% | 80.83% | 73.39% | 87.20% | 534.30% | $9.65B |
Sarepta Therapeutics, Inc.SRPT | 14.3% | 4.06% | -3.14% | -17.30% | 3.64% | -15.38% | 8.65% | -70.85% | -21.27% | -84.79% | -81.68% | $1.92B |
Scholar Rock Holding CorporationSRRK | 14.3% | 0.00% | -14.11% | -22.74% | -8.58% | -4.20% | -4.68% | 29.69% | 2.95% | 43.10% | 53.40% | $5.06B |
Soleno Therapeutics, Inc.SLNO | 14.3% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | $1.06B |
Ultragenyx Pharmaceutical Inc.RARE | 14.3% | 2.69% | 6.11% | 6.85% | 3.66% | -33.52% | -34.63% | -56.77% | -51.71% | -71.31% | -81.27% | $1.51B |
uniQure N.V.QURE | 14.3% | -2.59% | -42.37% | -51.00% | -3.55% | -5.81% | 44.21% | 112.24% | -64.59% | 280.74% | -25.98% | $1.56B |
| Theme return | — | 1.80% | -6.58% | -14.78% | -0.61% | 11.76% | 10.30% | 26.38% | -5.68% | 8.26% | -10.97% | — |
| Average | 14.3% | 1.80% | -6.58% | -12.42% | -0.04% | 2.00% | 3.39% | 23.96% | -15.96% | 32.20% | 44.17% | $3.22B |
| Median | 14.3% | 0.84% | -2.90% | -5.97% | 0.61% | -4.20% | 0.00% | 29.69% | -21.27% | 0.00% | -25.98% | $1.76B |
| Std Dev | 0.0% | 3.08% | 16.27% | 18.63% | 4.29% | 24.11% | 22.66% | 64.92% | 43.85% | 115.99% | 205.86% | $2.90B |
| Min | 14.3% | -2.59% | -42.37% | -51.00% | -8.58% | -33.52% | -34.63% | -70.85% | -64.59% | -84.79% | -89.56% | $1.06B |
| Max | 14.3% | 7.60% | 10.33% | 6.85% | 3.96% | 40.16% | 44.21% | 112.24% | 73.39% | 280.74% | 534.30% | $9.65B |
| % Positive Tickers | 57.14% | 28.57% | 28.57% | 57.14% | 28.57% | 42.86% | 57.14% | 28.57% | 42.86% | 28.57% |